The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bevacizumab Monoclonal Antibody Biosimilar Market Research Report 2025

Global Bevacizumab Monoclonal Antibody Biosimilar Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1739057

No of Pages : 69

Ask Your Query

Report Description
Table of Content

Synopsis
Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

Global Bevacizumab Monoclonal Antibody Biosimilar market is projected to reach US$ 471.5 million in 2029, increasing from US$ 1341 million in 2022, with the CAGR of -14.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bevacizumab Monoclonal Antibody Biosimilar market research.

Key manufacturers engaged in the Bevacizumab Monoclonal Antibody Biosimilar industry include Celltrion, Amneal, Pfizer and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Bevacizumab Monoclonal Antibody Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Bevacizumab Monoclonal Antibody Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Bevacizumab Monoclonal Antibody Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

Celltrion
Amneal
Pfizer
Amgen

Segment by Type

400mg
100mg

Segment by Application

Cancer
Wet Age-related Macular Degeneration
Other

Consumption by Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Russia)
Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
Latin America (Mexico, Brazil, Argentina)
Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Bevacizumab Monoclonal Antibody Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Bevacizumab Monoclonal Antibody Biosimilar Market Overview
1.1 Product Overview and Scope of Bevacizumab Monoclonal Antibody Biosimilar
1.2 Bevacizumab Monoclonal Antibody Biosimilar Segment by Type
1.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 400mg
1.2.3 100mg
1.3 Bevacizumab Monoclonal Antibody Biosimilar Segment by Application
1.3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Value by Application: (2023-2029)
1.3.2 Cancer
1.3.3 Wet Age-related Macular Degeneration
1.3.4 Other
1.4 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue 2018-2029
1.4.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales 2018-2029
1.4.3 Global Bevacizumab Monoclonal Antibody Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bevacizumab Monoclonal Antibody Biosimilar Market Competition by Manufacturers
2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Bevacizumab Monoclonal Antibody Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, Product Type & Application
2.7 Bevacizumab Monoclonal Antibody Biosimilar Market Competitive Situation and Trends
2.7.1 Bevacizumab Monoclonal Antibody Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bevacizumab Monoclonal Antibody Biosimilar Players Market Share by Revenue
2.7.3 Global Bevacizumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bevacizumab Monoclonal Antibody Biosimilar Retrospective Market Scenario by Region
3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2029
3.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2023
3.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Region: 2024-2029
3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Region: 2024-2029
3.4 North America Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.4.1 North America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.4.3 North America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2018-2029)
4.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023)
4.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Type (2024-2029)
4.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Bevacizumab Monoclonal Antibody Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2018-2029)
5.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023)
5.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales by Application (2024-2029)
5.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Celltrion
6.1.1 Celltrion Corporation Information
6.1.2 Celltrion Description and Business Overview
6.1.3 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.1.5 Celltrion Recent Developments/Updates
6.2 Amneal
6.2.1 Amneal Corporation Information
6.2.2 Amneal Description and Business Overview
6.2.3 Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amneal Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.2.5 Amneal Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Bevacizumab Monoclonal Antibody Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Monoclonal Antibody Biosimilar Industry Chain Analysis
7.2 Bevacizumab Monoclonal Antibody Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Monoclonal Antibody Biosimilar Production Mode & Process
7.4 Bevacizumab Monoclonal Antibody Biosimilar Sales and Marketing
7.4.1 Bevacizumab Monoclonal Antibody Biosimilar Sales Channels
7.4.2 Bevacizumab Monoclonal Antibody Biosimilar Distributors
7.5 Bevacizumab Monoclonal Antibody Biosimilar Customers
8 Bevacizumab Monoclonal Antibody Biosimilar Market Dynamics
8.1 Bevacizumab Monoclonal Antibody Biosimilar Industry Trends
8.2 Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
8.3 Bevacizumab Monoclonal Antibody Biosimilar Market Challenges
8.4 Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}